ABBV
NYSE:ABBV
AbbVie Inc.
- Stock
193.34
−0.90%
2.12
news - 5 hours ago
Emrelis Could Establish AbbVie as a Competitor in MET-High NSCLC Treatment
The article discusses AbbVie's antibody-drug conjugate (ADC) Emrelis, which may position the company as a key player in MET-high non-small cell lung cancer (NSCLC) treatment. With positive Phase III results, Emrelis could become the standard of care for MET-high NSCLC patients, differentiating AbbVie from competitors like Daiichi Sankyo, Seagen, and ImmunoGen. The FDA's accelerated approval signals confidence in biomarker-driven ADCs, while Emrelis' precision-targeting approach and potential for combination therapies highlight its strategic value in oncology.
pharmexec.comnews - 5 hours ago
Eli Lilly’s Cancer Drug Demonstrates Better Effectiveness Than AbbVie’s In Late Stage Trial: Retail Believes In Holding The Stock
Eli Lilly announced that its cancer drug Jaypirca outperformed AbbVie’s Imbruvica in a late-stage trial for treating chronic lymphocytic leukemia/small lymphocytic lymphoma. The study showed a higher overall response rate for Jaypirca. Lilly plans further testing on progression-free survival. Shares of Eli Lilly fell 5% after Novo Nordisk cut its sales guidance, though JPMorgan maintains an 'Overweight' rating with a $1,100 price target. Lilly’s stock has declined 0.4% this year and 5% over 12 months.
stocktwits.comnews - 11 hours ago
AbbVie (ABBV) Reports Q2: Everything You Need To Know Ahead Of Earnings
Pharmaceutical company AbbVie is set to report Q2 earnings, beating revenue expectations by 3.3% to $13.34 billion, with analysts predicting a 4% year-on-year revenue growth to $15.04 billion. Incyte, a peer in the biotechnology sector, also exceeded revenue estimates. AbbVie's stock is up 3% amid analyst price targets of $210.08.
markets.financialcontent.comnews - Jul 29, 2025 - 21:05
Trump's pharmaceutical tariffs could affect some drugmakers more than others
President Trump's potential pharmaceutical tariffs could disproportionately impact drugmakers based on their manufacturing networks. Analysts note that companies with significant U.S. manufacturing presence, like AbbVie, Bristol Myers Squibb, and Eli Lilly, are relatively well-positioned, while those with more overseas operations, such as Novartis and Roche, face higher risks. Tariffs could strain cash flow, prompt price hikes, and influence R&D strategies, though political and economic factors may limit their effectiveness.
cnbc.comnews - Jul 29, 2025 - 20:22
Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?
The article discusses whether AbbVie's stock is a must-have in a portfolio, focusing on its Pre-Q2 earnings performance and potential investment value.
zacks.comDescription
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients;...Show More
Earnings
Earnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus